Geynisman DM - Search Results

1

Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer.

Handorf EA, Beck JR, Correa A, Ramamurthy C, Geynisman DM. Handorf EA, et al. Among authors: geynisman dm. Med Decis Making. 2023 Oct-Nov;43(7-8):949-960. doi: 10.1177/0272989X231201621. Epub 2023 Oct 9. Med Decis Making. 2023. PMID: 37811793 Free PMC article.

2

Doctor, where art thou?

Geynisman DM. Geynisman DM. J Clin Oncol. 2013 Apr 20;31(12):1606-8. doi: 10.1200/JCO.2012.48.2059. Epub 2013 Mar 11. J Clin Oncol. 2013. PMID: 23478058 No abstract available.

3

A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.

Geynisman DM, Szmulewitz RZ, Stadler WM. Geynisman DM, et al. Eur Urol. 2012 Nov;62(5):864-6. doi: 10.1016/j.eururo.2012.08.030. Epub 2012 Aug 25. Eur Urol. 2012. PMID: 22939385 Clinical Trial. No abstract available.

4

Adherence to targeted oral anticancer medications.

Geynisman DM, Wickersham KE. Geynisman DM, et al. Discov Med. 2013 Apr;15(83):231-41. Discov Med. 2013. PMID: 23636140 Free PMC article. Review.

5

Reply to M.R. Litzow et al.

Geynisman DM. Geynisman DM. J Clin Oncol. 2013 Oct 10;31(29):3723-4. doi: 10.1200/JCO.2013.51.8431. Epub 2013 Sep 9. J Clin Oncol. 2013. PMID: 24019547 No abstract available.

6

A review of economic impact of targeted oral anticancer medications.

Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. Shen C, et al. Among authors: geynisman dm. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69. doi: 10.1586/14737167.2014.868310. Epub 2013 Dec 30. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24378038 Review.

7

Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis.

Carson-Walter EB, Hampton J, Shue E, Geynisman DM, Pillai PK, Sathanoori R, Madden SL, Hamilton RL, Walter KA. Carson-Walter EB, et al. Among authors: geynisman dm. Clin Cancer Res. 2005 Nov 1;11(21):7643-50. doi: 10.1158/1078-0432.CCR-05-1099. Clin Cancer Res. 2005. PMID: 16278383

8

Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.

Sadiq AA, Geynisman DM, Salgia R. Sadiq AA, et al. Among authors: geynisman dm. J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1810-1. doi: 10.1097/01.JTO.0000407568.45147.43. J Thorac Oncol. 2011. PMID: 22005540 Free article. No abstract available.

9

A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite.

Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. Zibelman M, et al. Among authors: geynisman dm. Clin Genitourin Cancer. 2015 Apr;13(2):142-9. doi: 10.1016/j.clgc.2014.08.005. Epub 2014 Sep 28. Clin Genitourin Cancer. 2015. PMID: 25450029 Review.

10

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma.

Geynisman DM, Handorf E, Wong YN, Doyle J, Plimack ER, Horwitz EM, Canter DJ, Uzzo RG, Kutikov A, Smaldone MC. Geynisman DM, et al. Cancer Med. 2016 Feb;5(2):192-9. doi: 10.1002/cam4.577. Epub 2015 Dec 18. Cancer Med. 2016. PMID: 26679712 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page